SJS Investment Consulting’s CytomX Therapeutics CTMX Stock Holding History

SJS Investment Consulting’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$870	Buy	+232	New	+$886	﹤0.01%	2073

Other funds holding CTMX

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Aspire Growth Partners Miromar Lakes, Florida $172M AUM 33.61% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SJS Investment Consulting's CTMX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 232 shares worth $870. The stake represents ﹤0.01% of the portfolio and ranks #2073 among its holdings.

22 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

SJS Investment Consulting held 232 shares of CytomX Therapeutics worth $870 as of Q2 2026.
CytomX Therapeutics was a new SJS Investment Consulting position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2073 holding.
22 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.